Industry News

Ventana, Boehringer Ingelheim to Collaborate on Development of Companion Diagnostics for Oncology

Ventana Medical Systems

Ventana Medical Systems Inc, Tucson, Ariz, a member of the Roche Group, and Boehringer Ingelheim, Germany, plan to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

Ventana will use its immunohistochemistry technology platform, experience, and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim’s personalized medicine healthcare strategies for cancer drug development.

Boehringer Ingelheim

Companion diagnostic tests provide information that helps physicians choose targeted treatments for their patients based on the expected best response to therapy. By integrating the development of companion diagnostic kits and drug candidates, Boehringer Ingelheim aims to yield cancer treatments with optimized benefit risk profiles.

In addition to Boehringer Ingelheim, Ventana has worked with more than 45 biopharma partners in the past decade and is engaged in more than 150 collaborative projects to develop and commercialize companion diagnostics globally.

[Source: Ventana Medical Systems]